Clean Hands

Chapter 1: The Numbers

The fluorescent lights in Lab 4B hummed their familiar monotone as Vivian Sato scrolled through the Phase III trial data for the fourth consecutive hour. Her coffee had gone cold two hours ago, and the cleaning crew had already passed through twice, their vacuum cleaners a distant drone in the corridor. But Vivian couldn't leave. Not yet. Not until she understood what she was seeing.

Neurovex-7 was supposed to be the breakthrough they'd all been waiting for—a disease-modifying treatment for Alzheimer's that actually worked. The preliminary results had been nothing short of miraculous. Patients showing measurable cognitive improvement. Plaque reduction in brain scans. Families crying tears of joy during follow-up appointments.

Vivian had been part of this project for three years, ever since joining Meridian Pharmaceuticals as a junior researcher fresh from her postdoc at Stanford. She'd watched Gerald Hoffman, the project director, present their findings at conferences to standing ovations. She'd seen the stock price triple. She'd believed.

But the numbers on her screen told a different story.

She'd stumbled onto the discrepancy by accident, really. A routine quality check on the adverse event reports had led her to cross-reference the raw data from the Chicago trial site with the compiled results in the final submission package. The Chicago site had reported seventeen cases of severe cardiac arrhythmia among their participants. The compiled data showed three.

Vivian had assumed it was a clerical error. A misplaced decimal, a transposed digit—the kind of mistake that happened in complex trials and got caught in review. She'd pulled the data from the Boston site to compare.

Boston had reported twelve cases of unexplained liver enzyme elevation. The compiled data showed two.

San Francisco. Twenty-three instances of dangerous blood pressure spikes. Compiled data: four.

For three hours now, Vivian had been methodically checking every trial site against the final submission. The pattern was unmistakable. Someone had systematically reduced the adverse event numbers by roughly eighty percent across the board. Someone had taken a drug with serious, potentially fatal side effects and made it look safe.

Vivian's hands trembled as she saved the comparison spreadsheet to her personal drive. Her throat felt tight, and when she finally pushed back from her desk, her legs were unsteady beneath her.

The FDA advisory committee was scheduled to vote on approval in three weeks. Meridian had already begun manufacturing. The marketing team had filmed commercials featuring elderly patients reuniting with their families, remembering grandchildren's names for the first time in years.

And somewhere in those commercials, Vivian knew, was a woman who looked remarkably like her mother.

Her phone buzzed. A text from the memory care facility: "Your mother had a good day today. She asked about you."

Vivian stared at the message until the screen went dark. Her mother, Keiko Sato, had been diagnosed with early-onset Alzheimer's at fifty-eight. She was sixty-three now, and the good days were becoming rare enough to warrant special notification. The disease had taken her ability to cook the elaborate Japanese meals she'd once prepared for every family gathering. It had taken her memory of Vivian's wedding, her divorce, her career. Some days it took her memory of Vivian entirely.

Neurovex-7 was supposed to change everything. Vivian had allowed herself to hope—had encouraged her father to hope—that her mother might be among the first patients to receive the drug once it was approved. That they might get her back, even partially. Even briefly.

Now Vivian understood that hope had been built on lies.

She gathered her things mechanically, shutting down her computer but leaving the comparison spreadsheet saved to the cloud. Her badge beeped as she exited the building into the warm California night, the parking lot nearly empty save for a few cars belonging to the truly dedicated or the truly desperate.

Vivian didn't know which category she fell into anymore.

The drive home took twenty minutes, but she barely remembered it. Her apartment was dark and silent, the plants on her windowsill drooping from neglect. She'd been working seventy-hour weeks for months, pushing toward the finish line of FDA approval. Her ex-husband David had cited her devotion to work as one of the reasons for their divorce, and standing in her empty kitchen at midnight, Vivian couldn't entirely disagree with his assessment.

She poured herself a glass of wine and sat at her small dining table, staring at her laptop. The spreadsheet was right there, waiting. The evidence of what Gerald Hoffman had done—what he was still doing—was irrefutable.

But what was she supposed to do with it?

Vivian had worked in pharmaceutical research long enough to understand the stakes. Neurovex-7 represented a fifteen-billion-dollar market opportunity. Meridian's entire future rested on its approval. Hundreds of jobs, thousands of investors, and yes, millions of patients were counting on this drug.

Including her mother.

The thought made her stomach turn. If she reported the falsified data, the FDA would almost certainly delay approval pending a full investigation. That investigation could take years. Her mother didn't have years. The disease was progressing steadily, stealing more of Keiko Sato with each passing month. By the time a reformulated drug might be available—if it ever was—there might be nothing left to save.

But if she stayed silent, and the drug was approved, and people started dying from cardiac arrhythmias and liver failure and strokes—

Vivian finished her wine in one long swallow. She thought about the seventeen patients in Chicago whose heart problems had been erased from the record. They were real people. They had families too. They had trusted Meridian Pharmaceuticals to tell the truth about what this drug might do to them.

She opened her laptop and began composing an email to Gerald Hoffman. She would give him a chance to explain. Maybe there was something she'd missed, some legitimate reason for the discrepancies. Maybe she was wrong.

She didn't believe it for a second, but she had to try.

"Dr. Hoffman," she typed, "I need to speak with you urgently regarding the Phase III adverse event data. I've found some inconsistencies that require immediate attention. Please let me know when you're available tomorrow."

She hit send before she could change her mind, then sat in the darkness listening to her own breathing. Sleep, she knew, would not come easily tonight.